<VariationArchive VariationID="37756" VariationName="NM_000059.4(BRCA2):c.1794_1798del" VariationType="Deletion" Accession="VCV000037756" Version="42" RecordType="classified" NumberOfSubmissions="25" NumberOfSubmitters="25" DateLastUpdated="2024-07-29" DateCreated="2014-04-01" MostRecentSubmission="2024-06-17">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="46312" VariationID="37756">
      <GeneList>
        <Gene Symbol="BRCA2" FullName="BRCA2 DNA repair associated" GeneID="675" HGNC_ID="HGNC:1101" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>13q13.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="13" Accession="NC_000013.11" start="32315508" stop="32400268" display_start="32315508" display_stop="32400268" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="13" Accession="NC_000013.10" start="32889616" stop="32973808" display_start="32889616" display_stop="32973808" Strand="+" />
          </Location>
          <OMIM>600185</OMIM>
          <Haploinsufficiency last_evaluated="2021-07-14" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=BRCA2">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-07-14" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=BRCA2">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2022</Property>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
        </Gene>
      </GeneList>
      <Name>NM_000059.4(BRCA2):c.1794_1798del</Name>
      <CanonicalSPDI>NC_000013.11:32333271:ATCTTAT:AT</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>13q13.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="13" Accession="NC_000013.11" start="32333272" stop="32333276" display_start="32333272" display_stop="32333276" variantLength="5" positionVCF="32333271" referenceAlleleVCF="CATCTT" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="13" Accession="NC_000013.10" start="32907409" stop="32907413" display_start="32907409" display_stop="32907413" variantLength="5" positionVCF="32907408" referenceAlleleVCF="CATCTT" alternateAlleleVCF="C" />
      </Location>
      <OtherNameList>
        <Name>2022del5</Name>
        <Name>2024_2028delCTTAT</Name>
        <Name>2024del5</Name>
      </OtherNameList>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_293" sequenceAccession="LRG_293">
            <Expression>LRG_293:g.22795_22799del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="U43746.1" sequenceAccession="U43746" sequenceVersion="1" change="c.1796_1800del">
            <Expression>U43746.1:c.1796_1800del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000059.4" sequenceAccession="NM_000059" sequenceVersion="4" change="c.1794_1798del" MANESelect="true">
            <Expression>NM_000059.4:c.1794_1798del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001587" Type="nonsense" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000059.3" sequenceAccession="NM_000059" sequenceVersion="3" change="c.1796_1800delCTTAT">
            <Expression>NM_000059.3:c.1796_1800delCTTAT</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="non-coding">
          <NucleotideExpression sequenceAccessionVersion="U43746.1" sequenceAccession="U43746" sequenceVersion="1" change="n.2024_2028delTTTAT">
            <Expression>U43746.1:n.2024_2028delTTTAT</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000013.10" sequenceAccession="NC_000013" sequenceVersion="10" change="g.32907411_32907415del" Assembly="GRCh37">
            <Expression>NC_000013.10:g.32907411_32907415del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000013.11" sequenceAccession="NC_000013" sequenceVersion="11" change="g.32333274_32333278del" Assembly="GRCh38">
            <Expression>NC_000013.11:g.32333274_32333278del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_012772.3" sequenceAccession="NG_012772" sequenceVersion="3" change="g.22795_22799del">
            <Expression>NG_012772.3:g.22795_22799del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000059.4" sequenceAccession="NM_000059" sequenceVersion="4" change="c.1796_1800del" MANESelect="true">
            <Expression>NM_000059.4:c.1796_1800del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000050.3" sequenceAccession="NP_000050" sequenceVersion="3" change="p.Thr598_Ser599insTer">
            <Expression>NP_000050.3:p.Thr598_Ser599insTer</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001587" Type="nonsense" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="2022&amp;base_change=del ATTTT" DB="Breast Cancer Information Core (BIC) (BRCA2)" />
        <XRef ID="2024&amp;base_change=del TTTAT" DB="Breast Cancer Information Core (BIC) (BRCA2)" />
        <XRef ID="CA013253" DB="ClinGen" />
        <XRef Type="rs" ID="276174813" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000059.4(BRCA2):c.1794_1798del AND Breast-ovarian cancer, familial, susceptibility to, 2" Accession="RCV000031337" Version="22">
        <ClassifiedConditionList TraitSetID="2560">
          <ClassifiedCondition DB="MedGen" ID="C2675520">Breast-ovarian cancer, familial, susceptibility to, 2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>reviewed by expert panel</ReviewStatus>
            <Description DateLastEvaluated="2016-04-22" SubmissionCount="11">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000059.4(BRCA2):c.1794_1798del AND not provided" Accession="RCV000043887" Version="28">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2023-05-11" SubmissionCount="5">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000059.4(BRCA2):c.1794_1798del AND Hereditary cancer-predisposing syndrome" Accession="RCV000129987" Version="18">
        <ClassifiedConditionList TraitSetID="13598">
          <ClassifiedCondition DB="MedGen" ID="C0027672">Hereditary cancer-predisposing syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2022-03-09" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000059.4(BRCA2):c.1794_1798del AND Hereditary breast ovarian cancer syndrome" Accession="RCV000168232" Version="23">
        <ClassifiedConditionList TraitSetID="7920">
          <ClassifiedCondition DB="MedGen" ID="C0677776">Hereditary breast ovarian cancer syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2024-01-12" SubmissionCount="3">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000059.4(BRCA2):c.1794_1798del AND Malignant tumor of breast" Accession="RCV001353530" Version="9">
        <ClassifiedConditionList TraitSetID="25616">
          <ClassifiedCondition DB="MedGen" ID="C0006142">Malignant tumor of breast</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000059.4(BRCA2):c.1794_1798del AND multiple conditions" Accession="RCV002490434" Version="7">
        <ClassifiedConditionList TraitSetID="19216">
          <ClassifiedCondition DB="MedGen" ID="C2675520">Breast-ovarian cancer, familial, susceptibility to, 2</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0346153">Familial cancer of breast</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1838457">Fanconi anemia complementation group D1</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C2751641">Glioma susceptibility 3</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0376358">Malignant tumor of prostate</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0025149">Medulloblastoma</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C3150546">Pancreatic cancer, susceptibility to, 2</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="CN033288">Wilms tumor 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-07-14" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000059.4(BRCA2):c.1794_1798del AND Familial cancer of breast" Accession="RCV003460499" Version="2">
        <ClassifiedConditionList TraitSetID="774">
          <ClassifiedCondition DB="MedGen" ID="C0346153">Familial cancer of breast</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-03-14" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000059.4(BRCA2):c.1794_1798del AND BRCA2-related disorder" Accession="RCV004532433" Version="1">
        <ClassifiedConditionList TraitSetID="33530">
          <ClassifiedCondition DB="MedGen" ID="CN239275">BRCA2-related disorder</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-02-14" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2016-04-22" NumberOfSubmissions="25" NumberOfSubmitters="25" DateCreated="2014-04-01" MostRecentSubmission="2024-06-17">
        <ReviewStatus>reviewed by expert panel</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">11504767</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">11754111</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">12142080</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15887246</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18694767</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18752448</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20104584</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22009639</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22085629</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22762150</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22798144</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24549055</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25371446</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26295337</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27062684</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">28294317</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">28724667</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29084914</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29335925</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29470806</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29907814</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">30014164</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">30702160</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">30720243</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">31396961</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">31444830</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">31871109</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">32427313</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">33471991</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">33629534</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">34645131</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">34657357</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">35535697</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8988179</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9150154</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="33530" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="36472" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">BRCA2-related condition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">BRCA2-related disorder</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">BRCA2-Related Disorders</ElementValue>
              </Name>
              <XRef ID="CN239275" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="25616" Type="Finding" ContributesToAggregateClassification="false">
            <Trait ID="34847" Type="Finding">
              <Name>
                <ElementValue Type="Preferred">Malignant tumor of breast</ElementValue>
                <XRef ID="254837009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Malignant breast neoplasm</ElementValue>
                <XRef ID="C9335" DB="NCI" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cancer breast</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000569423" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000604264" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="pmc">2936467</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1419</URL>
                <CitationText>Breast Cancer, NCCN Guidelines Version 4.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2018">
                <ID Source="PubMed">29939840</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479144</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2019">
                <ID Source="PubMed">30452337</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2018">
                <URL>https://www.nice.org.uk/guidance/dg34</URL>
                <CitationText>Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG34)</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/ng12</URL>
                <CitationText>UK NICE Guideline NG12, Suspected cancer: recognition and referral, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Breast Cancer, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2024">
                <URL>https://www.nice.org.uk/guidance/ng101</URL>
                <CitationText>UK NICE Guideline NG101, Early and locally advanced breast cancer: diagnosis and management, 2024</CitationText>
              </Citation>
              <XRef ID="C0006142" DB="MedGen" />
              <XRef ID="MONDO:0007254" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="2560" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="636" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Breast-ovarian cancer, familial 2</ElementValue>
                <XRef ID="Breast-ovarian+cancer%2C+familial+2/7866" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Breast-ovarian cancer, familial, susceptibility to, 2</ElementValue>
                <XRef ID="MONDO:0012933" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">BROVCA2</ElementValue>
                <XRef Type="MIM" ID="612555" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000531275" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509984" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551447" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000017874" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528915" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000519030" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000505644" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552245" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592961" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552304" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509450" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512644" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520071" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509001" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520867" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000320777" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000332529" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000604264" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520072" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000326160" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509002" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000527942" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509985" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000531340" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507653" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509692" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530202" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522160" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530707" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501748" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530120" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512645" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509980" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000021468" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000330054" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507864" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520870" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520865" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569423" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528916" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501818" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507764" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520394" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520871" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512816" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501744" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520869" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520872" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520866" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522159" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562228" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000325401" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569406" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520069" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The risk of developing an associated cancer varies depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant.</Attribute>
                <XRef ID="NBK1247" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301425</ID>
                <ID Source="BookShelf">NBK1247</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACS, 2007">
                <ID Source="PubMed">17392385</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="PubMed">20065170</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2007">
                <ID Source="PubMed">17508274</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2009">
                <ID Source="PubMed">19305347</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Phillips et al., 2013">
                <ID Source="PubMed">23918944</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Domchek et al., 2010">
                <ID Source="pmc">2948529</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014 [Archived]">
                <ID Source="PubMed">24366376</ID>
              </Citation>
              <Citation Type="general" Abbrev="CAPS, 2013">
                <ID Source="pmc">3585492</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2013">
                <ID Source="PubMed">23188549</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014">
                <ID Source="PubMed">24366402</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2013">
                <ID Source="PubMed">24432435</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2021">
                <ID Source="PubMed">33410258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2015">
                <ID Source="PubMed">26324357</ID>
              </Citation>
              <Citation Type="general" Abbrev="CAPS, 2020">
                <ID Source="PubMed">31672839</ID>
                <ID Source="pmc">7295005</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2022">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31429903</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479213</ID>
                <ID Source="BookShelf">NBK545867</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Hereditary-Breast-Ovarian-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <XRef ID="145" DB="Orphanet" />
              <XRef ID="C2675520" DB="MedGen" />
              <XRef ID="MONDO:0012933" DB="MONDO" />
              <XRef Type="MIM" ID="612555" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="13598" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="18746" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Tumor predisposition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cancer predisposition</ElementValue>
                <XRef ID="Hereditary+Cancer/3345" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary neoplastic syndrome</ElementValue>
                <XRef ID="MONDO:0015356" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neoplastic Syndromes, Hereditary</ElementValue>
                <XRef ID="D009386" DB="MeSH" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary Cancer Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hereditary cancer-predisposing syndrome</ElementValue>
                <XRef ID="699346009" DB="SNOMED CT" />
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="19921" />
                <XRef ID="19921" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="general" Abbrev="IARC, 2008">
                <ID Source="pmc">3075918</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <XRef ID="140162" DB="Orphanet" />
              <XRef ID="C0027672" DB="MedGen" />
              <XRef ID="D009386" DB="MeSH" />
              <XRef ID="MONDO:0015356" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="774" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="536" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Familial cancer of breast</ElementValue>
                <XRef ID="Familial+cancer+of+breast/8375" DB="Genetic Alliance" />
                <XRef ID="254843006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Breast cancer, familial</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17142" />
                <XRef ID="17142" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000530707" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000531340" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591268" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000561700" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569423" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558503" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562228" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The risk of developing an associated cancer varies depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant.</Attribute>
                <XRef ID="NBK1247" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301425</ID>
                <ID Source="BookShelf">NBK1247</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="review" Abbrev="Stratton and Rahman, 2008">
                <ID Source="PubMed">18163131</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2007">
                <ID Source="PubMed">17508274</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014 [Archived]">
                <ID Source="PubMed">24366376</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014">
                <ID Source="PubMed">24366402</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2013">
                <ID Source="PubMed">24432435</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1419</URL>
                <CitationText>Breast Cancer, NCCN Guidelines Version 4.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2022">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="St. Gallen, 2021">
                <ID Source="PubMed">34242744</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31429903</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479213</ID>
                <ID Source="BookShelf">NBK545867</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Hereditary-Breast-Ovarian-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2024">
                <URL>https://www.nice.org.uk/guidance/ng101</URL>
                <CitationText>UK NICE Guideline NG101, Early and locally advanced breast cancer: diagnosis and management, 2024</CitationText>
              </Citation>
              <XRef ID="227535" DB="Orphanet" />
              <XRef ID="C0346153" DB="MedGen" />
              <XRef ID="MONDO:0016419" DB="MONDO" />
              <XRef Type="MIM" ID="114480" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="19216" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="4506" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Wilms tumor, somatic</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Wilms tumor 1</ElementValue>
                <XRef ID="MONDO:0008679" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">WT1</ElementValue>
                <XRef Type="MIM" ID="194070" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">PAX6-related aniridia occurs either as an isolated ocular abnormality or as part of the Wilms tumor-aniridia-genital anomalies-retardation (WAGR) syndrome. Aniridia is a pan ocular disorder affecting the cornea, iris, intraocular pressure (resulting in glaucoma), lens (cataract and lens subluxation), fovea (foveal hypoplasia), and optic nerve (optic nerve coloboma and hypoplasia). Individuals with aniridia characteristically show nystagmus and impaired visual acuity (usually 20/100 - 20/200); however, milder forms of aniridia with subtle iris architecture changes, good vision, and normal foveal structure do occur. Other ocular involvement may include strabismus and occasionally microphthalmia. Although the severity of aniridia can vary between and within families, little variability is usually observed in the two eyes of an affected individual. WAGR syndrome. The risk for Wilms tumor is 42.5%-77%; of those who develop Wilms tumor, 90% do so by age four years and 98% by age seven years. Genital anomalies in males can include cryptorchidism and hypospadias (sometimes resulting in ambiguous genitalia), urethral strictures, ureteric abnormalities, and gonadoblastoma. While females typically have normal external genitalia, they may have uterine abnormalities and streak ovaries. Intellectual disability (defined as IQ &lt;74) is observed in 70%; behavioral abnormalities include attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder, anxiety, depression, and obsessive-compulsive disorder. Other individuals with WAGR syndrome can have normal intellect without behavioral problems.</Attribute>
                <XRef ID="NBK1360" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15124" />
                <XRef ID="15124" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301471</ID>
                <ID Source="BookShelf">NBK1294</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301534</ID>
                <ID Source="BookShelf">NBK1360</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">32352694</ID>
                <ID Source="BookShelf">NBK556455</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/wilms_tumor.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Wilms Tumor (Nephroblastoma), 2023</CitationText>
              </Citation>
              <XRef ID="654" DB="Orphanet" />
              <XRef ID="CN033288" DB="MedGen" />
              <XRef ID="MONDO:0008679" DB="MONDO" />
              <XRef Type="MIM" ID="194070" DB="OMIM" />
            </Trait>
            <Trait ID="6902" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Glioma susceptibility 3</ElementValue>
                <XRef ID="Glioma+susceptibility+3/8470" DB="Genetic Alliance" />
                <XRef ID="MONDO:0013093" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glioblastoma 3</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">GLM3</ElementValue>
                <XRef Type="MIM" ID="613029" DB="OMIM" />
              </Symbol>
              <XRef ID="182067" DB="Orphanet" />
              <XRef ID="360" DB="Orphanet" />
              <XRef ID="C2751641" DB="MedGen" />
              <XRef ID="MONDO:0013093" DB="MONDO" />
              <XRef Type="MIM" ID="613029" DB="OMIM" />
            </Trait>
            <Trait ID="536" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Familial cancer of breast</ElementValue>
                <XRef ID="Familial+cancer+of+breast/8375" DB="Genetic Alliance" />
                <XRef ID="254843006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Breast cancer, familial</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17142" />
                <XRef ID="17142" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000530707" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000531340" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591268" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000561700" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569423" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558503" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562228" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The risk of developing an associated cancer varies depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant.</Attribute>
                <XRef ID="NBK1247" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301425</ID>
                <ID Source="BookShelf">NBK1247</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="review" Abbrev="Stratton and Rahman, 2008">
                <ID Source="PubMed">18163131</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2007">
                <ID Source="PubMed">17508274</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014 [Archived]">
                <ID Source="PubMed">24366376</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014">
                <ID Source="PubMed">24366402</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2013">
                <ID Source="PubMed">24432435</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1419</URL>
                <CitationText>Breast Cancer, NCCN Guidelines Version 4.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2022">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="St. Gallen, 2021">
                <ID Source="PubMed">34242744</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31429903</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479213</ID>
                <ID Source="BookShelf">NBK545867</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Hereditary-Breast-Ovarian-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2024">
                <URL>https://www.nice.org.uk/guidance/ng101</URL>
                <CitationText>UK NICE Guideline NG101, Early and locally advanced breast cancer: diagnosis and management, 2024</CitationText>
              </Citation>
              <XRef ID="227535" DB="Orphanet" />
              <XRef ID="C0346153" DB="MedGen" />
              <XRef ID="MONDO:0016419" DB="MONDO" />
              <XRef Type="MIM" ID="114480" DB="OMIM" />
            </Trait>
            <Trait ID="1276" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Fanconi anemia complementation group D1</ElementValue>
                <XRef ID="MONDO:0011584" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">FAD1</ElementValue>
                <XRef Type="MIM" ID="605724" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">FANCD1</ElementValue>
                <XRef Type="MIM" ID="605724" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17449" />
                <XRef ID="17449" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Fanconi anemia (FA) is characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy. Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia. The incidence of acute myeloid leukemia is 13% by age 50 years. Solid tumors – particularly of the head and neck, skin, and genitourinary tract – are more common in individuals with FA.</Attribute>
                <XRef ID="NBK1401" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <Citation Type="Suggested Reading">
                <ID Source="PubMed">14559878</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301471</ID>
                <ID Source="BookShelf">NBK1294</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301575</ID>
                <ID Source="BookShelf">NBK1401</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="FARF, 2008">
                <URL>http://www.fanconi.org/images/uploads/other/Guidelines_for_Diagnosis_and_Management.pdf</URL>
                <CitationText>Fanconi Anemia Research Fund, Guidelines for Diagnosis and Management (3rd Ed.), 2008 (See 2020 Update)</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="FARF, 2020">
                <URL>https://www.fanconi.org/explore/clinical-care-guidelines</URL>
                <CitationText>Fanconi Anemia Clinical Care Guidelines, Fifth Edition.</CitationText>
              </Citation>
              <XRef ID="319462" DB="Orphanet" />
              <XRef ID="C1838457" DB="MedGen" />
              <XRef ID="MONDO:0011584" DB="MONDO" />
              <XRef Type="MIM" ID="605724" DB="OMIM" />
            </Trait>
            <Trait ID="636" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Breast-ovarian cancer, familial 2</ElementValue>
                <XRef ID="Breast-ovarian+cancer%2C+familial+2/7866" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Breast-ovarian cancer, familial, susceptibility to, 2</ElementValue>
                <XRef ID="MONDO:0012933" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">BROVCA2</ElementValue>
                <XRef Type="MIM" ID="612555" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000531275" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509984" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551447" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000017874" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528915" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000519030" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000505644" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552245" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592961" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552304" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509450" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512644" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520071" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509001" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520867" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000320777" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000332529" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000604264" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520072" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000326160" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509002" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000527942" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509985" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000531340" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507653" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509692" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530202" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522160" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530707" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501748" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530120" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512645" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509980" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000021468" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000330054" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507864" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520870" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520865" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569423" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528916" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501818" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507764" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520394" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520871" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512816" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501744" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520869" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520872" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520866" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522159" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562228" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000325401" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569406" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520069" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The risk of developing an associated cancer varies depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant.</Attribute>
                <XRef ID="NBK1247" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301425</ID>
                <ID Source="BookShelf">NBK1247</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACS, 2007">
                <ID Source="PubMed">17392385</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="PubMed">20065170</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2007">
                <ID Source="PubMed">17508274</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2009">
                <ID Source="PubMed">19305347</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Phillips et al., 2013">
                <ID Source="PubMed">23918944</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Domchek et al., 2010">
                <ID Source="pmc">2948529</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014 [Archived]">
                <ID Source="PubMed">24366376</ID>
              </Citation>
              <Citation Type="general" Abbrev="CAPS, 2013">
                <ID Source="pmc">3585492</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2013">
                <ID Source="PubMed">23188549</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014">
                <ID Source="PubMed">24366402</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2013">
                <ID Source="PubMed">24432435</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2021">
                <ID Source="PubMed">33410258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2015">
                <ID Source="PubMed">26324357</ID>
              </Citation>
              <Citation Type="general" Abbrev="CAPS, 2020">
                <ID Source="PubMed">31672839</ID>
                <ID Source="pmc">7295005</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2022">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31429903</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479213</ID>
                <ID Source="BookShelf">NBK545867</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Hereditary-Breast-Ovarian-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <XRef ID="145" DB="Orphanet" />
              <XRef ID="C2675520" DB="MedGen" />
              <XRef ID="MONDO:0012933" DB="MONDO" />
              <XRef Type="MIM" ID="612555" DB="OMIM" />
            </Trait>
            <Trait ID="2738" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Medulloblastoma, somatic</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Medulloblastoma</ElementValue>
                <XRef ID="Medulloblastoma/4552" DB="Genetic Alliance" />
                <XRef ID="HP:0002885" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0007959" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">MEDULLOBLASTOMA PREDISPOSITION SYNDROME</ElementValue>
                <XRef Type="MIM" ID="155255" DB="OMIM" />
                <XRef Type="Allelic variant" ID="612250.0002" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MDB</ElementValue>
                <XRef Type="MIM" ID="155255" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7005" />
                <XRef ID="7005" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Central Nervous System Cancers, 2023</CitationText>
              </Citation>
              <XRef ID="616" DB="Orphanet" />
              <XRef ID="C0025149" DB="MedGen" />
              <XRef ID="D008527" DB="MeSH" />
              <XRef ID="MONDO:0007959" DB="MONDO" />
              <XRef Type="MIM" ID="155255" DB="OMIM" />
              <XRef Type="primary" ID="HP:0002885" DB="Human Phenotype Ontology" />
            </Trait>
            <Trait ID="6821" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Pancreatic cancer 2</ElementValue>
                <XRef ID="Pancreatic+cancer+2/9069" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Pancreatic cancer, susceptibility to, 2</ElementValue>
                <XRef ID="MONDO:0013235" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">PNCA2</ElementValue>
                <XRef Type="MIM" ID="613347" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The risk of developing an associated cancer varies depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant.</Attribute>
                <XRef ID="NBK1247" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301425</ID>
                <ID Source="BookShelf">NBK1247</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Hereditary-Breast-Ovarian-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <XRef ID="1333" DB="Orphanet" />
              <XRef ID="C3150546" DB="MedGen" />
              <XRef ID="MONDO:0013235" DB="MONDO" />
              <XRef Type="MIM" ID="613347" DB="OMIM" />
            </Trait>
            <Trait ID="5807" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Prostate cancer</ElementValue>
                <XRef ID="HP:0012125" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0008315" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Malignant tumor of prostate</ElementValue>
                <XRef ID="Prostate+cancer/9175" DB="Genetic Alliance" />
                <XRef ID="399068003" DB="SNOMED CT" />
              </Name>
              <Citation Type="general" Abbrev="NACB, 2008">
                <ID Source="PubMed">19042984</ID>
              </Citation>
              <Citation Type="general" Abbrev="EGAPP, 2014">
                <ID Source="PubMed">24071797</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="NCCN, 2011">
                <ID Source="PubMed">22138009</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="AUA, 2018">
                <ID Source="PubMed">23659877</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Prostate cancer genetics">
                <ID Source="PubMed">26389227</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2024">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Prostate Cancer, 2024</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2021">
                <ID Source="PubMed">33497248</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2019">
                <ID Source="PubMed">31829902</ID>
              </Citation>
              <Citation Type="general" Abbrev="HKUA/HKSU-O, 2022">
                <ID Source="PubMed">35924163</ID>
                <ID Source="pmc">9339641</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/ng12</URL>
                <CitationText>UK NICE Guideline NG12, Suspected cancer: recognition and referral, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2021">
                <URL>https://www.nice.org.uk/guidance/ng131</URL>
                <CitationText>UK NICE Guideline NG131, Prostate cancer: diagnosis and management, 2021</CitationText>
              </Citation>
              <XRef ID="1331" DB="Orphanet" />
              <XRef ID="C0376358" DB="MedGen" />
              <XRef ID="MONDO:0008315" DB="MONDO" />
              <XRef Type="primary" ID="HP:0012125" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
          <TraitSet ID="7920" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="16761" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Hereditary breast and ovarian cancer</ElementValue>
                <XRef ID="UWMG_4506306" DB="CSER _CC_NCGL, University of Washington" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hereditary breast ovarian cancer syndrome</ElementValue>
                <XRef ID="MONDO:0003582" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Breast and ovarian cancer</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary breast and ovarian cancer syndrome (HBOC)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary breast and/or ovarian cancer syndrome</ElementValue>
                <XRef ID="145" DB="Orphanet" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary breast and ovarian cancer syndrome</ElementValue>
                <XRef ID="D061325" DB="MeSH" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">HBOC</ElementValue>
                <XRef ID="GTR000500933" DB="Genetic Testing Registry (GTR)" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The risk of developing an associated cancer varies depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant.</Attribute>
                <XRef ID="NBK1247" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15010" />
                <XRef ID="15010" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000530120" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509978" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530202" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509001" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522159" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530118" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509980" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509985" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000500933" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522278" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530028" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528916" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520071" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522161" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000325401" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000604264" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551448" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000521908" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558867" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000505644" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512699" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000521909" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509002" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000021517" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512816" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000017876" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507653" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552245" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000021468" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000502103" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558910" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520394" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592450" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000527942" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000595973" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507764" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501981" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000508566" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000508956" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520072" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591268" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562228" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569916" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000508948" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551441" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552302" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000325409" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520887" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522160" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509983" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551440" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000521499" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509982" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522559" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528915" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000561859" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000330054" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000503369" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000514601" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558503" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000017874" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552183" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509984" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000523320" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301425</ID>
                <ID Source="BookShelf">NBK1247</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACS, 2007">
                <ID Source="PubMed">17392385</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="PubMed">20065170</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2003">
                <ID Source="PubMed">12692171</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="review" Abbrev="Stratton and Rahman, 2008">
                <ID Source="PubMed">18163131</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2007">
                <ID Source="PubMed">17508274</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2009">
                <ID Source="PubMed">19305347</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Phillips et al., 2013">
                <ID Source="PubMed">23918944</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Domchek et al., 2010">
                <ID Source="pmc">2948529</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014 [Archived]">
                <ID Source="PubMed">24366376</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2013">
                <ID Source="PubMed">23188549</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014">
                <ID Source="PubMed">24366402</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2013">
                <ID Source="PubMed">24432435</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2021">
                <ID Source="PubMed">33410258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2015">
                <ID Source="PubMed">26324357</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2022">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31429903</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479213</ID>
                <ID Source="BookShelf">NBK545867</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Hereditary-Breast-Ovarian-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg122</URL>
                <CitationText>UK NICE Clinical guideline (CG122), Ovarian cancer: recognition and initial management, 2023</CitationText>
              </Citation>
              <XRef ID="145" DB="Orphanet" />
              <XRef ID="C0677776" DB="MedGen" />
              <XRef ID="D061325" DB="MeSH" />
              <XRef ID="MONDO:0003582" DB="MONDO" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="376407" SubmissionDate="2023-05-17" DateLastUpdated="2023-10-07" DateCreated="2015-02-24">
        <ClinVarSubmissionID localKey="GDXSV:271478" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV000210716" DateUpdated="2023-10-07" DateCreated="2015-02-24" Type="SCV" Version="19" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-05-11">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; Also known as 2024_2028del, 2024del5, and c.1794_1798del; This variant is associated with the following publications: (PMID: 12142080, 29470806, 30014164, 31794323, 31336956, 34413315, 32438681, 32875559, 30040829, 8988179, 22009639, 22085629, 24549055, 11754111, 27062684, 28724667, 29907814, 29084914, 29335925, 25371446, 22798144, 18694767, 15887246, 11504767, 9150154, 26295337, 22762150, 31209999, 30720243, 30702160, 31396961, 31444830, 31957001, 31447099, 33726785, 31825140, 30787465, 31742824, 30130155, 34645131, 35535697, 32427313, 31871109)</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification Process June 2021</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/fc81e176/genedx_variant_classification_process_june_2021.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Deletion</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">GDX:8065</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.1796_1800del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not Provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GeneDX_Clinvar_Submission_137_20221031152118</SubmissionName>
          <SubmissionName>GeneDX_Clinvar_Submission_18_20210720144155</SubmissionName>
          <SubmissionName>GeneDX_Clinvar_Submission_191_20230517054203</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="8794658" SubmissionDate="2024-03-08" DateLastUpdated="2024-03-16" DateCreated="2024-03-16">
        <ClinVarSubmissionID localKey="22671688|BRCA2-related condition" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004711871" DateUpdated="2024-03-16" DateCreated="2024-03-16" Type="SCV" Version="1" SubmitterName="PreventionGenetics, part of Exact Sciences" OrgID="239772" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-02-14">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The BRCA2 c.1796_1800del5 variant is predicted to result in premature protein termination (p.Ser599*). This variant has been reported to be causative for breast or ovarian cancer (described as c.2022del5, Gayther et al 1997. PubMed ID: 8988179; Azzollini. 2016. PubMed ID: 27062684 ; Table S2, Fostira. 2018. PubMed ID: 29335925). This variant is reported in 0.00090% of alleles in individuals of European (Non-Finnish) descent in gnomAD and is interpreted as pathogenic in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/37756/). Nonsense variants in BRCA2 are expected to be pathogenic. This variant is interpreted as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.1796_1800del5</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">BRCA2-related condition</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14299258</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="262838" SubmissionDate="2014-03-28" DateLastUpdated="2023-10-07" DateCreated="2014-04-01">
        <ClinVarSubmissionID localKey="U43746.1:n.2024_2028delTTTAT|MedGen:C2675520" />
        <ClinVarAccession Accession="SCV000145940" DateUpdated="2023-10-07" DateCreated="2014-04-01" Type="SCV" Version="2" SubmitterName="Breast Cancer Information Core (BIC) (BRCA2)" OrgID="504197" OrganizationCategory="locus-specific database (LSDB)" />
        <RecordStatus>current</RecordStatus>
        <ReplacedList>
          <Replaced Accession="SCV000145938" DateChanged="2017-03-26" Version="2" />
        </ReplacedList>
        <Classification DateLastEvaluated="2002-05-29">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="8" />
            </ObservedData>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <GeographicOrigin>Brazil</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="2" />
            </ObservedData>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <GeographicOrigin>Norway</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <GeographicOrigin>Sweden</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Caucasian</Ethnicity>
              <GeographicOrigin>Italy</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Western European</Ethnicity>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="3" />
            </ObservedData>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Western European, Italian</Ethnicity>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>U43746.1:exon 10</GeneLocation>
          </Location>
          <OtherNameList>
            <Name>2024del5</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">U43746.1:n.2024_2028delTTTAT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Breast-ovarian cancer, familial 2</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C2675520" Type="CUI" />
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1148212" SubmissionDate="2021-03-31" DateLastUpdated="2023-10-07" DateCreated="2017-08-27">
        <ClinVarSubmissionID localKey="chr13:32907407-32907413:d5423cbcb2bd7c3be6a3196162f410a6-BREAST" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000591768" DateUpdated="2023-10-07" DateCreated="2017-08-27" Type="SCV" Version="3" SubmitterName="Department of Pathology and Laboratory Medicine, Sinai Health System" OrgID="506152" OrganizationCategory="laboratory" OrgAbbreviation="PLM-SHS" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="506759" SubmitterName="Franklin by Genoox" Type="secondary" OrganizationCategory="other" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The p.Ser599X variant was identified in 2 of 816 proband chromosomes (frequency: 0.002) from individuals or families with breast and ovarian cancer (Gayther 1997, Bayraktar 2012). The variant was also identified in dbSNP (ID: rs276174813) â€šÃ„ÃºWith pathogenic alleleâ€šÃ„Ã¹, HGMD, the ClinVar database (classified as a pathogenic variant by the BIC and Invitae), GeneInsight VariantWire database (1X, classified as â€šÃ„Ãºpathogenicâ€šÃ„Ã¹ by a clinical laboratory), the BIC database (12X with clinical importance) and UMD (15X as a causal variant). The p.Ser599X variant leads to a premature stop codon at position 599, which is predicted to lead to a truncated or absent protein and loss of function. Loss of function variants of the BRCA2 gene are an established mechanism of disease in hereditary breast and ovarian cancer and is the type of variant expected to cause the disorder. In summary, based on the above information, this variant meets our laboratoryâ€šÃ„Ã´s criteria to be classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="13" alternateAllele="C" referenceAllele="CATCTT" start="32907408" stop="32907413" variantLength="6" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0007254" />
          </Trait>
        </TraitSet>
        <StudyName>The Canadian Open Genetics Repository (COGR)</StudyName>
        <SubmissionNameList>
          <SubmissionName>SUB9371647</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1360915" SubmissionDate="2022-10-13" DateLastUpdated="2023-10-07" DateCreated="2017-08-27">
        <ClinVarSubmissionID localKey="NM_000059.3:c.1796_1800delCTTAT|MedGen:C0677776" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000694563" DateUpdated="2023-10-07" DateCreated="2017-08-27" Type="SCV" Version="3" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-09-19">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">12142080</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22009639</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22798144</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11504767</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18694767</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25371446</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">28294317</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29907814</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">31871109</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">32427313</ID>
          </Citation>
          <Comment>Variant summary: BRCA2 c.1796_1800delCTTAT (p.Ser599X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 4.1e-06 in 244054 control chromosomes. c.1796_1800delCTTAT has been reported in the literature in multiple individuals affected with Hereditary Breast And Ovarian Cancer Syndrome (e.g. Kim_2012, Lang_2017, Palmer_2020). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. 13 clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.1796_1800delCTTAT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0677776" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2016-2017-variants</SubmissionName>
          <SubmissionName>SUB12153506</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1328878" SubmissionDate="2017-06-22" DateLastUpdated="2023-10-07" DateCreated="2017-03-27">
        <ClinVarSubmissionID localKey="54944|OMIM:612555" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000677720" DateUpdated="2023-10-07" DateCreated="2017-03-27" Type="SCV" Version="3" SubmitterName="Counsyl" OrgID="320494" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-03-20">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">9150154</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12142080</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8988179</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Counsyl Autosomal Dominant Disease Classification criteria (2015)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/qikq0wz6/counsyl_autosomal_dominant_disease_classification_criteria_2015__v1_4_2_.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.1796_1800del5</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612555" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB2805501</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5453660" SubmissionDate="2022-12-13" DateLastUpdated="2023-10-07" DateCreated="2022-12-31">
        <ClinVarSubmissionID localKey="NM_000059.3:c.1796_1800del|OMIM:114480;155255;176807;194070;605724;612555;613029;613347" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002804078" DateUpdated="2023-10-07" DateCreated="2022-12-31" Type="SCV" Version="2" SubmitterName="Fulgent Genetics, Fulgent Genetics" OrgID="500105" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-07-14">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.1796_1800del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="TraitChoice">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="114480" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="155255" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="176807" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="194070" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="605724" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612555" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="613029" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="613347" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12390657</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="119825" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2013-07-03">
        <ClinVarSubmissionID localKey="518424|MedGen:C0677776" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000071900" DateUpdated="2024-02-14" DateCreated="2013-07-03" Type="SCV" Version="14" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <ReplacedList>
          <Replaced Accession="SCV000218901" DateChanged="2015-10-09" Version="1" />
        </ReplacedList>
        <Classification DateLastEvaluated="2024-01-12">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">20104584</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8988179</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22009639</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22085629</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22798144</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24549055</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Ser599*) in the BRCA2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA2 are known to be pathogenic (PMID: 20104584). This variant is present in population databases (rs276174813, gnomAD 0.0009%). This premature translational stop signal has been observed in individual(s) with breast cancer (PMID: 8988179, 22009639, 22085629, 22798144, 24549055). This variant is also known as c.1796delCTTAT and 2024del5. ClinVar contains an entry for this variant (Variation ID: 37756). RNA analysis performed to evaluate the impact of this premature translational stop signal on mRNA splicing indicates it does not significantly alter splicing (Invitae). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000013.10:g.32907409_32907413del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0677776" Type="CUI" />
          </Trait>
        </TraitSet>
        <Citation Type="general">
          <ID Source="PubMed">28492532</ID>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7863516" SubmissionDate="2024-06-05" DateLastUpdated="2024-06-17" DateCreated="2023-12-30">
        <ClinVarSubmissionID localKey="NM_000059.4:c.1796_1800del|OMIM:114480" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004216147" DateUpdated="2024-06-17" DateCreated="2023-12-30" Type="SCV" Version="2" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-03-14">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.4:c.1796_1800del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="114480" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GA_HC_20231102_20240331</SubmissionName>
          <SubmissionName>SUB13856327</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="537092" SubmissionDate="2016-06-09" DateLastUpdated="2023-10-07" DateCreated="2016-06-24">
        <ClinVarSubmissionID localKey="NM_000059.3:c.1796_1800del5|OMIM:612555" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000282361" DateUpdated="2023-10-07" DateCreated="2016-06-24" Type="SCV" Version="2" SubmitterName="Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA)" OrgID="504863" OrganizationCategory="consortium" OrgAbbreviation="ENIGMA" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2016-04-22">
          <ReviewStatus>reviewed by expert panel</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>Variant allele predicted to encode a truncated non-functional protein.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ENIGMA BRCA1/2 Classification Criteria (2015)</Attribute>
          <Citation Type="general">
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/c2ffjci6/enigma_rules_2015-03-26.pdf</URL>
            <CitationText>ENIGMA BRCA1/2 Classification Criteria (2015)</CitationText>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>2024_2028delCTTAT</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.1796_1800del5</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612555" Type="MIM" />
          </Trait>
        </TraitSet>
        <StudyDescription>ENIGMA (Evidence-based Network for the Interpretation of Germline Mutant Alleles) is a consortium focused on determining the clinical significance of variants in BRCA1, BRCA2 and other known/suspected breast cancer genes. http://enigmaconsortium.org/</StudyDescription>
        <SubmissionNameList>
          <SubmissionName>ENIGMA_2015-08-17</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="89557" SubmissionDate="2015-12-29" DateLastUpdated="2023-10-07" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="SCRP_var_386" title="NM_000059.3:c.1796_1800delCTTAT AND Breast-ovarian cancer, familial 2" />
        <ClinVarAccession Accession="SCV000053942" DateUpdated="2023-10-07" DateCreated="2013-04-04" Type="SCV" Version="5" SubmitterName="Sharing Clinical Reports Project (SCRP)" OrgID="500037" OrganizationCategory="consortium" OrgAbbreviation="SCRP" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2011-05-02">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
              <NumberTested>10</NumberTested>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles">10</Attribute>
            </ObservedData>
            <Co-occurrenceSet>
              <Zygosity>SingleHeterozygote</Zygosity>
              <AlleleDescSet>
                <Name>BRCA2:5864A&gt;G (E1879G)</Name>
                <Zygosity>SingleHeterozygote</Zygosity>
                <ClinicalSignificance>
                  <ReviewStatus>no assertion criteria provided</ReviewStatus>
                  <Description>Uncertain significance</Description>
                </ClinicalSignificance>
              </AlleleDescSet>
              <Count>1</Count>
            </Co-occurrenceSet>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="nucleotide change">2024del5</Name>
          </OtherNameList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Breast-ovarian cancer, familial 2</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1637474" SubmissionDate="2018-06-14" DateLastUpdated="2023-10-07" DateCreated="2017-03-27">
        <ClinVarSubmissionID localKey="NM_000059.3:c.1796_1800del|OMIM:612555" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000839921" DateUpdated="2023-10-07" DateCreated="2017-03-27" Type="SCV" Version="2" SubmitterName="Human Genome Sequencing Center Clinical Lab, Baylor College of Medicine" OrgID="500199" OrganizationCategory="laboratory" OrgAbbreviation="HGSC-CL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-05-25">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The c.1796_1800del (p.Ser599*) variant in the BRCA2 gene has been detected multiple patients with breast cancer [reported as 2022del5 in PMID 8988179]. This variant creates a premature stop codon at amino acid position 599 of the BRCA2 protein. This variant is thus predicted to result in a loss of function of the protein. This variant has not been observed in the ExAC population database. This variant thus classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.1796_1800del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612555" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB4151980</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2857544" SubmissionDate="2020-10-23" DateLastUpdated="2023-10-07" DateCreated="2020-11-28">
        <ClinVarSubmissionID localKey="report_configuration_variant_id:500" />
        <ClinVarAccession Accession="SCV001447156" DateUpdated="2023-10-07" DateCreated="2020-11-28" Type="SCV" Version="2" SubmitterName="Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen" OrgID="506385" OrganizationCategory="laboratory" OrgAbbreviation="IMGAG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-10-23">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Unknown mechanism</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <NumberTested>1</NumberTested>
              <Gender>female</Gender>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="SampleLocalID">DX183543</Attribute>
            </ObservedData>
            <TraitSet Type="Finding">
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0003002" />
              </Trait>
            </TraitSet>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="13" alternateAllele="C" referenceAllele="CATCTT" start="32907408" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3427507" SubmissionDate="2021-06-30" DateLastUpdated="2023-10-07" DateCreated="2021-07-07">
        <ClinVarSubmissionID localKey="NM_000059.4:c.1794_1798del|OMIM:612555" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001739442" DateUpdated="2023-10-07" DateCreated="2021-07-07" Type="SCV" Version="2" SubmitterName="Clinical Cancer Genomics Laboratory, City of Hope Comprehensive Cancer Center" OrgID="508098" OrganizationCategory="other" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-01-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Latin American</Ethnicity>
              <GeographicOrigin>San Juan, PR</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">30</Age>
              <Age Type="maximum" age_unit="years">39</Age>
              <AffectedStatus>no</AffectedStatus>
              <Gender>female</Gender>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.4:c.1794_1798del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612555" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB9926389</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3746145" SubmissionDate="2021-09-20" DateLastUpdated="2023-10-07" DateCreated="2021-09-24">
        <ClinVarSubmissionID localKey=":Chr.13_32907408_32907413_CATCTT_C|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001905987" DateUpdated="2023-10-07" DateCreated="2021-09-24" Type="SCV" Version="2" SubmitterName="Clinical Genetics Laboratory, Department of Pathology, Netherlands Cancer Institute" OrgID="506537" OrganizationCategory="clinic" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="506382" SubmitterName="Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen" Type="behalf" OrganizationCategory="laboratory" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="13" alternateAllele="C" referenceAllele="CATCTT" start="32907408" stop="32907413" variantLength="6" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <StudyName>VKGL Data-share Consensus</StudyName>
        <SubmissionNameList>
          <SubmissionName>SUB10399800</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3787837" SubmissionDate="2021-09-23" DateLastUpdated="2023-10-07" DateCreated="2021-09-24">
        <ClinVarSubmissionID localKey=":Chr.13_32907408_32907413_CATCTT_C|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001930456" DateUpdated="2023-10-07" DateCreated="2021-09-24" Type="SCV" Version="2" SubmitterName="Genome Diagnostics Laboratory, University Medical Center Utrecht" OrgID="274978" OrganizationCategory="laboratory" OrgAbbreviation="GDL-UMCU" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="506382" SubmitterName="Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen" Type="behalf" OrganizationCategory="laboratory" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="13" alternateAllele="C" referenceAllele="CATCTT" start="32907408" stop="32907413" variantLength="6" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <StudyName>VKGL Data-share Consensus</StudyName>
        <SubmissionNameList>
          <SubmissionName>SUB10419633</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4966706" SubmissionDate="2022-06-09" DateLastUpdated="2023-10-07" DateCreated="2022-06-24">
        <ClinVarSubmissionID localKey="NM_000059.4:c.1796_1800del|OMIM:612555" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV002538624" DateUpdated="2023-10-07" DateCreated="2022-06-24" Type="SCV" Version="2" SubmitterName="Laan Lab, Human Genetics Research Group, University of Tartu" OrgID="508159" OrganizationCategory="laboratory" OrgAbbreviation="LL_HGRG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-05-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">35535697</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <Description>exome sequencing</Description>
              <MethodType>research</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SingleHeterozygote" integerValue="1" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SecondaryFinding">yes</Attribute>
            </ObservedData>
            <TraitSet Type="Finding">
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0011961" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0100243" />
              </Trait>
            </TraitSet>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.4:c.1796_1800del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612555" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11567626</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="625719" SubmissionDate="2016-10-28" DateLastUpdated="2023-10-07" DateCreated="2016-11-05">
        <ClinVarSubmissionID localKey="NM_000059.3:c.1796_1800del|OMIM:612555" submittedAssembly="hg18" />
        <ClinVarAccession Accession="SCV000326611" DateUpdated="2023-10-07" DateCreated="2016-11-05" Type="SCV" Version="5" SubmitterName="Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), c/o University of Cambridge" OrgID="505954" OrganizationCategory="consortium" OrgAbbreviation="CIMBA" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2015-10-02">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">CIMBA Mutation Classification guidelines May 2016</Attribute>
          <Citation Type="general">
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/nhgqiuyb/cimba_mutation_classification_guidelines_may16.pdf</URL>
            <CitationText>CIMBA_Mutation_Classification_guidelines_May16.pdf</CitationText>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
              <FamilyData NumFamiliesWithVariant="37" />
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.1796_1800del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612555" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>CIMBA_20161005</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7113260" SubmissionDate="2023-03-01" DateLastUpdated="2023-10-07" DateCreated="2023-03-04">
        <ClinVarSubmissionID localKey="ca1c5e701b138ac8c94adede508de490" localKeyIsSubmitted="1" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV003807161" DateUpdated="2023-10-07" DateCreated="2023-03-04" Type="SCV" Version="2" SubmitterName="Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein" OrgID="508506" OrganizationCategory="laboratory" OrgAbbreviation="LABO-HIAE" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-12-22">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>ACMG classification criteria: PVS1 very strong, PS4 strong, PM2 moderated</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <GeographicOrigin>Brazil</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <NumberTested>1</NumberTested>
            </Sample>
            <Method>
              <Description>Paired-end whole-genome sequencing</Description>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <GeographicOrigin>Brazil</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <NumberTested>1</NumberTested>
            </Sample>
            <Method>
              <Description>Paired-end whole-genome sequencing</Description>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.4:c.1796_1800del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612555" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12925816</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7555833" SubmissionDate="2023-08-31" DateLastUpdated="2023-10-07" DateCreated="2023-09-30">
        <ClinVarSubmissionID localKey="chr13:32907408" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004037368" DateUpdated="2023-10-07" DateCreated="2023-09-30" Type="SCV" Version="2" SubmitterName="Division Of Personalized Genomic Medicine, Columbia University Irving Medical Center" OrgID="508215" OrganizationCategory="laboratory" OrgAbbreviation="PGL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-12-10">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal dominant inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Tissue>peripheral blood</Tissue>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">50</Age>
              <Age Type="maximum" age_unit="years">59</Age>
              <AffectedStatus>unknown</AffectedStatus>
              <NumberTested>1</NumberTested>
              <Gender>male</Gender>
              <Proband>yes</Proband>
            </Sample>
            <Method>
              <TypePlatform>Sanger sequencing</TypePlatform>
              <Purpose>validation</Purpose>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="SingleHeterozygote" integerValue="1" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SecondaryFinding">yes</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.4:c.1796_1800delCTTAT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612555" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13808666</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1737649" SubmissionDate="2023-12-22" DateLastUpdated="2024-01-06" DateCreated="2019-03-13">
        <ClinVarSubmissionID localKey="S125|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000887761" DateUpdated="2024-01-06" DateCreated="2019-03-13" Type="SCV" Version="5" SubmitterName="Quest Diagnostics Nichols Institute San Juan Capistrano" OrgID="500110" OrganizationCategory="laboratory" OrgAbbreviation="Quest Diagnostics" />
        <RecordStatus>current</RecordStatus>
        <ReplacedList>
          <Replaced Accession="SCV000296660" DateChanged="2022-12-29" Version="2">
            <Comment Type="MergeComment">SCV000296660 was merged into SCV000887761 to remove duplication.</Comment>
          </Replaced>
        </ReplacedList>
        <Classification DateLastEvaluated="2021-09-24">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">29335925</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29084914</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25371446</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8988179</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22762150</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22798144</ID>
          </Citation>
          <Comment>This frameshift variant causes the premature termination of BRCA2 protein synthesis. In addition, it has been reported in individuals and families affected with breast/ovarian cancer in the published literature (PMID: 8988179 (1997), 22798144 (2012), 25371446 (2014), 29084914 (2018), 29335925 (2018)). Based on the available information, this variant is classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Quest Diagnostics criteria</Attribute>
          <Citation>
            <ID Source="PubMed">26467025</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.1796_1800del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12490872</SubmissionName>
          <SubmissionName>SUB14108248</SubmissionName>
          <SubmissionName>SUB4481696</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7928517" SubmissionDate="2024-02-05" DateLastUpdated="2024-02-14" DateCreated="2024-02-14">
        <ClinVarSubmissionID localKey="BCLV000397|MedGen:C2675520" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004244231" DateUpdated="2024-02-14" DateCreated="2024-02-14" Type="SCV" Version="1" SubmitterName="BRCAlab, Lund University" OrgID="508740" OrganizationCategory="laboratory" OrgAbbreviation="BRCAlab" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-03-02">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000013.10:g.32907411_32907415del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C2675520" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>BCLS000001</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1338992" SubmissionDate="2024-01-25" DateLastUpdated="2024-02-14" DateCreated="2018-02-19">
        <ClinVarSubmissionID localKey="Db4KrQBSZeoE7-orUyypkY8cvu9XVUJhXsjmRr-lrEw|MedGen:C0027672" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000683449" DateUpdated="2024-02-14" DateCreated="2018-02-19" Type="SCV" Version="5" SubmitterName="Color Diagnostics, LLC DBA Color Health" OrgID="505849" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-03-09">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">9150154</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11754111</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12142080</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15887246</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18694767</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18752448</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22009639</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25371446</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29084914</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">33471991</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">33629534</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">34645131</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">34657357</ID>
          </Citation>
          <Comment>This variant deletes 5 nucleotides in exon 10 of the BRCA2 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in at least 15 individuals affected with breast, ovarian and/or endometrial cancer (PMID: 9150154, 11754111, 12142080, 15887246, 18694767, 18752448, 22009639, 25371446, 29084914, 33471991; Leiden Open Variation Database DB-ID BRCA2_001800, 33629534, 34657357, 34645131). This variant has been identified in 1/244054 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <TypePlatform>NGS</TypePlatform>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.4:c.1796_1800del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0027672" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>ColorClinVarSubmissionJune2021_SUB9834248</SubmissionName>
          <SubmissionName>SUB14171678</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="9056045" SubmissionDate="2024-04-19" DateLastUpdated="2024-04-20" DateCreated="2024-04-20">
        <ClinVarSubmissionID localKey="100906840|Orphanet:ORPHA145" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV004848363" DateUpdated="2024-04-20" DateCreated="2024-04-20" Type="SCV" Version="1" SubmitterName="Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine" OrgID="21766" OrganizationCategory="laboratory" OrgAbbreviation="LMM" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-06-19">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">8988179</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22009639</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27062684</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">28724667</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">30014164</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29335925</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29084914</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29907814</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29470806</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">30702160</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">31396961</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">30720243</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">31444830</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26295337</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25371446</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24549055</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22798144</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22762150</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22085629</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18694767</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15887246</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12142080</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11754111</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11504767</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">9150154</ID>
          </Citation>
          <Comment>The p.Ser599X variant (also reported as c.2022del5, c.2024_2028delCTTAT, and c.2024del5) in BRCA2 has been reported in the literature in &gt;15 individuals with BRCA2-related cancers and segregated with disease in at least three relatives (Gayther 1997, Håkansson 1997, Loman 2001, Ladopoulou 2002, Armakolas 2002, Bonadona 2005, Tommasi 2008, Kim 2012, Castéra 2014, Torres-Mejía 2015, Azzollini 2016, Barnes-Kedar 2018, Fostira 2018, Palmero 2018,Singh 2018,Bhaskaran 2019). This vairant has been identified in 1/111114 European chromosomes by gnomAD (http://gnomad.broadinstitute.org). This nonsense variant leads to a premature termination codon at position 599, which is predicted to lead to a truncated or absent protein. Loss of function of the BRCA2 gene is an established disease mechanism in autosomal dominant hereditary breast and ovarian cancer syndrome (HBOC). Additionally, this variant was classified as pathogenic on April 22, 2016 by the ClinGen-approved ENIGMA expert panel (ClinVar SCV000282361.1). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant HBOC. ACMG/AMP Criteria applied: PVS1; PM2; PS4, PP1.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>NM_000059.4:exon 10</GeneLocation>
          </Location>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000013.11:g.32333274_32333278delCTTAT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="Orphanet" ID="ORPHA145" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14389831</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="303326" SubmissionDate="2024-04-24" DateLastUpdated="2024-05-01" DateCreated="2014-08-06">
        <ClinVarSubmissionID localKey="a64197|MedGen:C0027672" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000184811" DateUpdated="2024-05-01" DateCreated="2014-08-06" Type="SCV" Version="9" SubmitterName="Ambry Genetics" OrgID="61756" OrganizationCategory="laboratory" OrgAbbreviation="Ambry" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-10-22">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">11504767</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11754111</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12142080</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15887246</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18694767</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22009639</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22798144</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25371446</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29084914</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29335925</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8988179</ID>
          </Citation>
          <Comment>The c.1796_1800delCTTAT pathogenic mutation (also known as p.S599*), located in coding exon 9 of the BRCA2 gene, results from a deletion of five nucleotides at positions 1796 to 1800. This changes the amino acid from a serine to a stop codon within coding exon 9. This mutation has been detected in female breast cancer, male breast cancer, and ovarian cancer cases (Gayther SA et al. Nat. Genet. 1997 Jan;15:103-5; Loman N et al. J. Natl. Cancer Inst. 2001 Aug;93:1215-23; Ladopoulou A et al. Cancer Lett. 2002 Nov;185:61-70; Kim H et al. Breast Cancer Res. Treat. 2012 Aug;134:1315-26; Torres-Mejia G et al. Cancer Epidemiol. Biomarkers Prev. 2015 Mar;24:498-505; Fostira F et al. Breast Cancer Res. Treat. 2018 May;169:105-113; Labidi-Galy SI et al. Clin. Cancer Res. 2018 Jan;24:326-333). Of note, this alteration is also designated as 2024del5 in published literature. In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Ambry Variant Classification Scheme 2023</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/i9igeqse/ambry_variant_classification_scheme_2023.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.1796_1800delCTTAT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0027672" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>All AVA3 Novel and Update Variants_103122</SubmissionName>
          <SubmissionName>FinalClinVarSubmissionFile_20140101to20240315_ava3_1</SubmissionName>
          <SubmissionName>NonExomeUpdate_081220AmbryReport</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="3787837" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7113260" TraitType="Disease" MappingType="XRef" MappingValue="612555" MappingRef="OMIM">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2857544" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5453660" TraitType="Disease" MappingType="XRef" MappingValue="613029" MappingRef="OMIM">
        <MedGen CUI="C2751641" Name="Glioma susceptibility 3" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4966706" TraitType="Finding" MappingType="XRef" MappingValue="HP:0011961" MappingRef="HP">
        <MedGen CUI="C4021107" Name="Non-obstructive azoospermia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="262838" TraitType="Disease" MappingType="Name" MappingValue="Breast-ovarian cancer, familial 2" MappingRef="Preferred">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5453660" TraitType="Disease" MappingType="XRef" MappingValue="176807" MappingRef="OMIM">
        <MedGen CUI="C2931456" Name="Familial prostate carcinoma" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="89557" TraitType="Disease" MappingType="Name" MappingValue="Breast-ovarian cancer, familial 2" MappingRef="Preferred">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7928517" TraitType="Disease" MappingType="XRef" MappingValue="C2675520" MappingRef="MedGen">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5453660" TraitType="Disease" MappingType="XRef" MappingValue="114480" MappingRef="OMIM">
        <MedGen CUI="C0346153" Name="Familial cancer of breast" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3427507" TraitType="Disease" MappingType="XRef" MappingValue="612555" MappingRef="OMIM">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="625719" TraitType="Disease" MappingType="XRef" MappingValue="612555" MappingRef="OMIM">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5453660" TraitType="Disease" MappingType="XRef" MappingValue="605724" MappingRef="OMIM">
        <MedGen CUI="C1838457" Name="Fanconi anemia complementation group D1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5453660" TraitType="Disease" MappingType="XRef" MappingValue="613347" MappingRef="OMIM">
        <MedGen CUI="C3150546" Name="Pancreatic cancer, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1148212" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0007254" MappingRef="MONDO">
        <MedGen CUI="C0006142" Name="Malignant tumor of breast" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1328878" TraitType="Disease" MappingType="XRef" MappingValue="612555" MappingRef="OMIM">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1338992" TraitType="Disease" MappingType="XRef" MappingValue="C0027672" MappingRef="MedGen">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="537092" TraitType="Disease" MappingType="XRef" MappingValue="612555" MappingRef="OMIM">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5453660" TraitType="Disease" MappingType="XRef" MappingValue="194070" MappingRef="OMIM">
        <MedGen CUI="CN033288" Name="Wilms tumor 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="376407" TraitType="Disease" MappingType="Name" MappingValue="Not Provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4966706" TraitType="Disease" MappingType="XRef" MappingValue="612555" MappingRef="OMIM">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7555833" TraitType="Disease" MappingType="XRef" MappingValue="612555" MappingRef="OMIM">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="303326" TraitType="Disease" MappingType="XRef" MappingValue="C0027672" MappingRef="MedGen">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1360915" TraitType="Disease" MappingType="XRef" MappingValue="C0677776" MappingRef="MedGen">
        <MedGen CUI="C0677776" Name="Hereditary breast ovarian cancer syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7863516" TraitType="Disease" MappingType="XRef" MappingValue="114480" MappingRef="OMIM">
        <MedGen CUI="C0346153" Name="Familial cancer of breast" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4966706" TraitType="Finding" MappingType="XRef" MappingValue="HP:0100243" MappingRef="HP">
        <MedGen CUI="C0023269" Name="Leiomyosarcoma" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2857544" TraitType="Finding" MappingType="XRef" MappingValue="HP:0003002" MappingRef="HP">
        <MedGen CUI="C0678222" Name="Breast carcinoma" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="8794658" TraitType="Disease" MappingType="Name" MappingValue="BRCA2-related condition" MappingRef="Preferred">
        <MedGen CUI="CN239275" Name="BRCA2-related disorder" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3746145" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5453660" TraitType="Disease" MappingType="XRef" MappingValue="612555" MappingRef="OMIM">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5453660" TraitType="Disease" MappingType="XRef" MappingValue="155255" MappingRef="OMIM">
        <MedGen CUI="C0025149" Name="Medulloblastoma" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1637474" TraitType="Disease" MappingType="XRef" MappingValue="612555" MappingRef="OMIM">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1737649" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="119825" TraitType="Disease" MappingType="XRef" MappingValue="C0677776" MappingRef="MedGen">
        <MedGen CUI="C0677776" Name="Hereditary breast ovarian cancer syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="9056045" TraitType="Disease" MappingType="XRef" MappingValue="ORPHA145" MappingRef="Orphanet">
        <MedGen CUI="C0677776" Name="Hereditary breast ovarian cancer syndrome" />
      </TraitMapping>
    </TraitMappingList>
    <DeletedSCVList>
      <SCV>
        <Accession Version="3" DateDeleted="2023-08-18">SCV002010732</Accession>
        <Description>not specified</Description>
      </SCV>
      <SCV>
        <Accession Version="1" DateDeleted="2021-11-13">SCV001852815</Accession>
        <Description>not specified</Description>
      </SCV>
    </DeletedSCVList>
  </ClassifiedRecord>
</VariationArchive>

